Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Got arthritis? DNAlytics has an app for it!

Approximately 30% of patients with undifferentiated arthritis develop rheumatoid arthritis - a chronic, inflammatory disease causing deformity of …


MiDiagnostics develops disposable chip for blood self-testing

MiDiagnostics is a new startup that will make disposable chips to test your own blood and saliva. Only 15 minutes after the test, you will be able…


More efficient aerosol therapy

Aerosol therapy is an important aspect of respiratory care. The drug-delivery efficiency depends on the deposition of the aerosol particles in the…

POPULAR TAGS

FDA support for FLUIDDA’s FRI-technology in lung fibrosis

Written by LVS on in the category news with the tags .


The US Food and Drug Administration has issued a letter of support for FLUIDDA’s Functional Respiratory Imaging (FRI) technology. The FDA encourages the use of FRI in clinical trials with patients suffering from Idiopathic Pulmonary Fibrosis (IPF).

IPF is characterized by the creation of scar tissue in the lungs that progressively reduces the capacity to properly move oxygen into the bloodstream. The median survival of patients with IPF is dramatic: only 2 to 3 years of life remain after diagnosis. The development of therapeutics for the disease is seriously hampered by the lack of biomarkers to use as clinical end points. Presently, no qualified markers are available to measure disease progression or treatment benefit.

FLUIDDA’s FRI-technology provides structural and functional information of the lung, derived from conventional low-dose CT scans. FRI is a promising tool to be used by pharmaceutical and biotech companies to expedite the development of new drugs. FRI has already proven its merit in lung disorders such as asthma and COPD. The FDA now highly recommends its use in the search for and development of better IPF biomarkers.

FLUIDDA’s CEO Dr. Jan De Backer states: “This is an important milestone for our company. Having the support of the FDA in the development of new biomarkers is crucial to facilitate further adoption of our technology. We are looking forward to continuing our collaboration with pharmaceutical and biotech companies who are committed to developing new and better drugs for this terrible disease.”

Read the FDA’s full letter of support here.

Read more about: .

RELATED ARTICLES
Got arthritis? DNAlytics has an app for it!

Approximately 30% of patients with undifferentiated arthritis develop rheumatoid arthritis - a chronic, inflammatory disease causing deformity of …


MiDiagnostics develops disposable chip for blood self-testing

MiDiagnostics is a new startup that will make disposable chips to test your own blood and saliva. Only 15 minutes after the test, you will be able…


More efficient aerosol therapy

Aerosol therapy is an important aspect of respiratory care. The drug-delivery efficiency depends on the deposition of the aerosol particles in the…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen Biowin Flanders.bio GSK Itera Life Science V-Bio Ventures XpandInnovation KU Leuven UGent Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.